SEC Form 4
Vir Biotechnology, Inc. (VIR) insider trading
In the 12 months to Nov 18, 2026, 9 VIR insiders reported open-market sales of $8.2M across 27 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $8.2M
- 27 filings · 9 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 27 of 27
- All $8.2M sold was pre-arranged
Who traded VIR, and when
- Sale
- Sale, pre-arranged (10b5-1)
VIR daily close from Nov 18, 2025 to Nov 17, 2026, between $5.44 and $13.65, last $9.25. 27 sale and 0 purchase filings by 9 insiders, marked at their filing dates. SVF Endurance (Cayman) Ltd, 10% owner: sold $4.1M across 2 filings, first filed Nov 26, 2025, last Dec 3, 2025. Vicki L. Sato, Director: sold $1.5M across 7 filings, first filed Dec 2, 2025, last May 4, 2026. SOFTBANK VISION FUND (AIV M1) L.P., 10% owner: sold $1.2M across 1 filing, first filed Dec 1, 2025, last Dec 1, 2025. Backer Marianne De, Chief Executive Officer → President and CEO: sold $947.0K across 3 filings, first filed Feb 24, 2026, last Apr 7, 2026. Verneuil Vanina de, EVP, General Counsel, Corp Sec: sold $239.3K across 3 filings, first filed Feb 24, 2026, last Nov 4, 2026. Brent Sabatini, SVP, Chief Accounting Officer: sold $113.1K across 5 filings, first filed Feb 18, 2026, last Jun 2, 2026. 3 others: sold $148.7K across 6 filings, first filed Nov 18, 2025, last Jun 2, 2026.
Largest mark · tap a row for others
SVF Endurance (Cayman) Ltd · 10% owner
Sale $2,906,278
463,774 shares at $6.27 avg
Filed Nov 26, 2025 · traded Nov 24
Pre-arranged (10b5-1) · close on filing date $6.39
SVF Endurance (Cayman) Ltd · 10% owner
10% owner
$4.1M soldVicki L. Sato · Director
Director
$1.5M soldSOFTBANK VISION FUND (AIV M1) L.P. · 10% owner
10% owner
$1.2M soldBacker Marianne De · Chief Executive Officer → President and CEO
Chief Executive Officer → President and CEO
$947.0K soldVerneuil Vanina de · EVP, General Counsel, Corp Sec
EVP, General Counsel, Corp Sec
$239.3K soldBrent Sabatini · SVP, Chief Accounting Officer
SVP, Chief Accounting Officer
$113.1K sold3 others
Combined, one mark per week
$148.7K soldOpen-market trades
27 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd | 10% owner | $4.1M | — | 2 | 100% of sales | |
| Vicki L. Sato | Director | $1.5M | — | 7 | 100% of sales | |
| SOFTBANK VISION FUND (AIV M1) L.P. | 10% owner | $1.2M | — | 1 | 100% of sales | |
| Backer Marianne De | Chief Executive Officer → President and CEO | $947.0K | — | 3 | 100% of sales | |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | $239.3K | — | 3 | 100% of sales | |
| Brent Sabatini | SVP, Chief Accounting Officer | $113.1K | — | 5 | 100% of sales | |
| Jason O'Byrne | EVP & Chief Financial Officer | $68.9K | — | 3 | 100% of sales | |
| Mark Eisner | EVP and Chief Medical Officer | $49.5K | — | 2 | 100% of sales | |
| Janet Napolitano | Director | $30.2K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Verneuil Vanina de EVP, General Counsel, Corp Sec | SalePre-arranged (10b5-1) | 3,750 | $11.18 | $41.9K | 110,193 | |
traded | Brent Sabatini SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 379 | $9.45 | $3.6K | 61,902 | |
traded | Janet Napolitano Director | SalePre-arranged (10b5-1) | 3,200 | $9.45 | $30.2K | 21,216 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $10.05 | $221.0K | 1,078,391 | |
traded | Backer Marianne De President and CEO | SalePre-arranged (10b5-1) | 72,559 | $9.16 | $664.4K | 948,145 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $9.07 | $199.6K | 1,100,391 | |
traded | Brent Sabatini SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 7,711 | $9.12 | $70.3K | 61,902 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $9.51 | $209.2K | 1,122,391 | |
traded | Backer Marianne De Chief Executive Officer | SalePre-arranged (10b5-1) | 14,762 | $9.53 | $140.7K | 1,020,704 | |
traded | Verneuil Vanina de EVP, General Counsel, Corp Sec | SalePre-arranged (10b5-1) | 16,817 | $9.77 | $164.2K | 112,982 | |
traded | Mark Eisner EVP and Chief Medical Officer | SalePre-arranged (10b5-1) | 3,505 | $9.69 | $34.0K | 154,024 | |
traded | Jason O'Byrne EVP & Chief Financial Officer | SalePre-arranged (10b5-1) | 1,634 | $9.53 | $15.6K | 162,615 | |
traded | Brent Sabatini SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 1,430 | $9.53 | $13.6K | 69,613 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 42,377 | $9.75 | $413.4K | 1,144,591 | |
traded | Backer Marianne De Chief Executive Officer | SalePre-arranged (10b5-1) | 19,039 | $7.45 | $141.9K | 1,035,466 | |
traded | Verneuil Vanina de EVP, General Counsel, Corp Sec | SalePre-arranged (10b5-1) | 4,445 | $7.45 | $33.1K | 129,799 | |
traded | Mark Eisner EVP and Chief Medical Officer | SalePre-arranged (10b5-1) | 2,089 | $7.45 | $15.6K | 157,529 | |
traded | Jason O'Byrne EVP & Chief Financial Officer | SalePre-arranged (10b5-1) | 2,089 | $7.45 | $15.6K | 164,249 | |
traded | Brent Sabatini SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 1,829 | $7.45 | $13.6K | 71,043 | |
traded | Brent Sabatini SVP, Chief Accounting Officer | SalePre-arranged (10b5-1) | 1,530 | $7.79 | $11.9K | 47,872 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $7.71 | $169.7K | 1,144,391 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $5.93 | $130.4K | 1,166,391 | |
traded | SVF Endurance (Cayman) Ltd 10% owner | SalePre-arranged (10b5-1) | 191,854 | $5.98 | $1.1M | 13,728,924 | |
traded | Vicki L. Sato Director | SalePre-arranged (10b5-1) | 22,000 | $6.00 | $132.1K | 1,188,391 | |
traded | SOFTBANK VISION FUND (AIV M1) L.P. 10% owner | SalePre-arranged (10b5-1) | 189,431 | $6.41 | $1.2M | 13,920,778 | |
traded | SVF Endurance (Cayman) Ltd 10% owner | SalePre-arranged (10b5-1) | 463,774 | $6.27 | $2.9M | 14,110,209 | |
traded | Jason O'Byrne EVP & Chief Financial Officer | SalePre-arranged (10b5-1) | 6,799 | $5.56 | $37.8K | 110,701 |
GET /stocks/filings/vX/form-4?tickers=VIR&filing_date.gte=2025-11-18&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"VIR"
],
"issuer_cik": "0001706431",
"owner_cik": "0002036234",
"accession_number": "0001628280-26-070025",
"form_type": "4",
"filing_date": "2026-11-04",
"period_of_report": "2026-11-02",
"issuer_name": "Vir Biotechnology, Inc.",
"issuer_trading_symbol": "VIR",
"owner_name": "de Verneuil Vanina",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, General Counsel, Corp Sec",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-03",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 2407,
"transaction_price_per_share": 11.1,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 110193,
"transaction_value": 26717.7,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F3",
"description": "The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026."
}
]
},
{
"tickers": [
"VIR"
],
"issuer_cik": "0001706431",
"owner_cik": "0002036234",
"accession_number": "0001628280-26-070025",
"form_type": "4",
"filing_date": "2026-11-04",
"period_of_report": "2026-11-02",
"issuer_name": "Vir Biotechnology, Inc.",
"issuer_trading_symbol": "VIR",
"owner_name": "de Verneuil Vanina",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "EVP, General Counsel, Corp Sec",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1343,
"transaction_price_per_share": 11.334,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 112600,
"transaction_value": 15221.562,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."
},
{
"id": "F2",
"description": "Includes 961 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 22 records
- Option exercises1 record
- Grants and awards15 records
- Other6 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Role
- The title on each filing. Someone whose title changed shows more than one.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- Counted once
- When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.
Frequently asked questions
Has Vir Biotechnology, Inc.'s CEO sold stock?
Yes. Backer Marianne De (CEO) sold 106,360 shares ($947.0K) between Feb 2026 and Apr 2026, all under a pre-arranged 10b5-1 plan.
How current is VIR’s insider data?
These are VIR Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track VIR insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for VIR every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.